Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
Oliver Gerhard OttmannCarsten Müller-TidowAlwin KrämerRichard F SchlenkMichael LübbertGesine BugUtz KrugTilmann BochtlerFlorian VossTillmann TaubeDan LiuPilar Garin-ChesaHartmut DöhnerPublished in: British journal of haematology (2018)
Keyphrases
- acute myeloid leukemia
- open label
- phase iii
- phase ii
- liver failure
- study protocol
- respiratory failure
- clinical trial
- acute lymphoblastic leukemia
- drug induced
- aortic dissection
- combination therapy
- high dose
- multiple myeloma
- bone marrow
- randomized controlled trial
- diffuse large b cell lymphoma
- dendritic cells
- hepatitis b virus
- intensive care unit
- acute respiratory distress syndrome